Loki's approval date depends on the regulatory body. In the United States, Lokelma (sodium zirconium cyclosilicate) was approved by the Food and Drug Administration (FDA) on June 26, 2018 [1].
How is Lokelma used to treat high potassium levels?
Lokelma is a medication prescribed to treat hyperkalemia, a condition characterized by abnormally high levels of potassium in the blood [2]. It works by binding to potassium in the gastrointestinal tract, preventing its absorption into the bloodstream [2]. This binding action helps to reduce serum potassium concentrations.
What is the typical dosage and administration for Lokelma?
The initial recommended dose for Lokelma is 10 grams administered orally three times a day [3]. After achieving a target serum potassium level, the maintenance dose can be adjusted to 10 grams once a day or 5 grams once a day, depending on the patient's response [3]. The medication can be taken with or without food and can be mixed with water or other liquids [2].
Are there any notable side effects associated with Lokelma?
Common side effects reported with Lokelma include gastrointestinal disturbances such as nausea, constipation, and diarrhea [2]. It is important for patients to report any persistent or bothersome side effects to their healthcare provider.
How does Lokelma compare to other potassium-lowering agents?
Lokelma offers a rapid onset of action for reducing potassium levels, often within the first hour of administration [1]. Unlike some other potassium binders that can cause constipation, Lokelma has shown a lower incidence of this side effect and may even help regulate bowel function for some patients [2]. Its mechanism of action involves selective binding to potassium, which contributes to its efficacy [2].
When does Lokelma's patent protection expire?
Patent expiration dates for pharmaceutical products are complex and can vary. Information regarding Lokelma's specific patent status and potential expiry dates can be found through resources like DrugPatentWatch.com [4].
---
Sources
1. US Food and Drug Administration. (2018, June 26). FDA approves Lokelma (sodium zirconium cyclosilicate) for oral suspension. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fda-approves-lokelma-sodium-zirconium-cyclosilicate-oral-suspension
2. AstraZeneca. (n.d.). Lokelma (sodium zirconium cyclosilicate) Prescribing Information. https://www.lokelma.com/docs/prescribing-information.pdf
3. National Institutes of Health. (n.d.). Sodium Zirconium Cyclosilicate. https://medlineplus.gov/druginfo/meds/a617038.html
4. DrugPatentWatch.com. (n.d.). Lokelma Patents. https://drugpatentwatch.com/